Your session is about to expire
← Back to Search
A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy
Phase 2
Waitlist Available
Research Sponsored by Cali Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 - 72 hours
Summary
This trial tests a new medication called CPL-01 to help manage pain in patients having open inguinal hernia repair surgery. Different doses are being tried to find the safest and most effective one.
Eligible Conditions
- Inguinal Hernia Repair
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0 - 72 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 - 72 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
AUC of the NRS-A for pain (Primary Endpoint)
Side effects data
From 2020 Phase 2 trial • 20 Patients • NCT0418288027%
Constipation
20%
Nausea
7%
Feeling Hot
7%
Hypoaesthesia
7%
Dizziness
7%
Dysgeusia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
CPL-01
Trial Design
3Treatment groups
Experimental Treatment
Group I: PlaceboExperimental Treatment1 Intervention
30mL normal saline (0.9%)
Group II: NaropinExperimental Treatment1 Intervention
150mg
Group III: CPL-01Experimental Treatment1 Intervention
CPL-01 200mg, 400mg, 600mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CPL-01
2020
Completed Phase 2
~130
Naropin 150 MG Per 20 ML Injection
2021
Completed Phase 2
~110
Placebo
1995
Completed Phase 3
~2670
Find a Location
Who is running the clinical trial?
Cali Pharmaceuticals LLCLead Sponsor
4 Previous Clinical Trials
1,171 Total Patients Enrolled
Erol Onel, MDStudy ChairCali Biosciences
5 Previous Clinical Trials
620 Total Patients Enrolled